Coverage of oncology medicines well aligned across Canadian provinces, but sources of funding differ

Patented Medicine Prices Review Board

4 May 2021 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, today published the second in a three part report series on Alignment Among Public Formularies in Canada. 

This latest report looks at gaps and overlaps in the coverage and funding of oncology drugs across Canada.

Read Patented Medicine Prices Review Board press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Canada